2-ARYLBENZO[b]THIOPHENES USEFUL FOR THE TREATMENT OF ESTROGEN DEPRIVATION SYNDROME

1. A method for inhibiting estrogen deprivation syndrome in mammals which includes administering to a mammal in need thereof an effective amount of a compound of formula I: where: R and R are independently hydrogen, hydroxy, or a solvate thereof. 2. A method according to Claim 1 where the mammal is a female human. 3. A method according to Claim 2 where the pathology of estrogen deprivation syndrome is osteoporosis. 4. A method according to Claim 2 where the pathology of estrogen deprivation syndrome is hyperlipidemia. 5. A use according to Claim 2 where the female human is peri- or post-menopausal. 6. A method for inhibiting estrogen deprivation syndrome in mammals which comprises administering to a mammal in need thereof an effective amount of a compound of formula I: where: R and R are independently hydroxy, or solvate thereof or a compound of formula II where: R and R are independently hydrogen, C1-C6 alkyl, CO (C1-C6 alkyl), or OCOAr; R is pyrolidin-1-yl, piperidin-1-yl, or hexamethyleneimin-1-yl; where the nitrogen of the R group is optionally the N-oxide; or a pharmaceutical salt or solvate thereof. 7. A method according to Claim 6 where the mammal is a female human. 8. A method according to Claim 7 where the pathology of said estrogen deprivation syndrome is osteoporosis. 9. A method according to Claim 8 where the pathology of said estrogen deprivation syndrome is hyperlipidemia. 10. A method according to Claim 6 where the compound of formula II is the hydrochloride salt, R and R are both hydrogen, and R is piperidin-1-yl. 11. A method according to Claim 7 where the female human is menopausal. 12. A method according to Claim 6 where said compound of formula I is 2-(4-hydroxyphenyl)-6-hydroxybenzo(b]thiophene, and said compound of formula II is raloxifene hydrochloride and pathology is osteoporosis. 13. A pharmaceutical formulation comprising a compound of formula I: where: R and R are independently hydroxy, or a solvate thereof, or a compound of formula II R and R are independently hydrogen, C1-C6 alkyl, CO(C1-C6 alkyl), or CQAr; R is pyrolidin-1-yl, piperidin-1-yl, or hexamethyleneimin-1-yl; where the nitrogen of the R group is optionally the N-oxide; or a pharmaceutical salt or solvate thereof; and pharmaceutical carriers, excipients, or diluents. 14. A formulation according to Claim 13 comprising 0.001 to 60 mg of a compound of formula I or a solvate thereof, and 1 to 120 mg of a compound of formula II being raloxifene hydrochloride. 15. A formul